These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 30711629)

  • 21. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells.
    Tong G; Cheng B; Li J; Wu X; Nong Q; He L; Li X; Li L; Wang S
    Cancer Med; 2019 Nov; 8(16):7044-7054. PubMed ID: 31557409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tivantinib Decreases Hepatocyte Growth Factor-Induced BCRP Expression in Hepatocellular Carcinoma HepG2 Cells.
    Kobayashi K; Higai K; Mukozu T; Matsui D; Amanuma M; Yoshimine N; Ogino Y; Matsui T; Wakui N; Shinohara M; Momiyama K; Daido Y; Nagai H; Igarashi Y
    Biol Pharm Bull; 2020; 43(9):1421-1425. PubMed ID: 32879217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for 'Off-Target' Effects Not Mediated by c-Met Inhibition.
    Reuther C; Heinzle V; Spampatti M; Vlotides G; de Toni E; Spöttl G; Maurer J; Nölting S; Göke B; Auernhammer CJ
    Neuroendocrinology; 2016; 103(3-4):383-401. PubMed ID: 26338447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
    Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
    Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
    Pfister D; Núñez NG; Pinyol R; Govaere O; Pinter M; Szydlowska M; Gupta R; Qiu M; Deczkowska A; Weiner A; Müller F; Sinha A; Friebel E; Engleitner T; Lenggenhager D; Moncsek A; Heide D; Stirm K; Kosla J; Kotsiliti E; Leone V; Dudek M; Yousuf S; Inverso D; Singh I; Teijeiro A; Castet F; Montironi C; Haber PK; Tiniakos D; Bedossa P; Cockell S; Younes R; Vacca M; Marra F; Schattenberg JM; Allison M; Bugianesi E; Ratziu V; Pressiani T; D'Alessio A; Personeni N; Rimassa L; Daly AK; Scheiner B; Pomej K; Kirstein MM; Vogel A; Peck-Radosavljevic M; Hucke F; Finkelmeier F; Waidmann O; Trojan J; Schulze K; Wege H; Koch S; Weinmann A; Bueter M; Rössler F; Siebenhüner A; De Dosso S; Mallm JP; Umansky V; Jugold M; Luedde T; Schietinger A; Schirmacher P; Emu B; Augustin HG; Billeter A; Müller-Stich B; Kikuchi H; Duda DG; Kütting F; Waldschmidt DT; Ebert MP; Rahbari N; Mei HE; Schulz AR; Ringelhan M; Malek N; Spahn S; Bitzer M; Ruiz de Galarreta M; Lujambio A; Dufour JF; Marron TU; Kaseb A; Kudo M; Huang YH; Djouder N; Wolter K; Zender L; Marche PN; Decaens T; Pinato DJ; Rad R; Mertens JC; Weber A; Unger K; Meissner F; Roth S; Jilkova ZM; Claassen M; Anstee QM; Amit I; Knolle P; Becher B; Llovet JM; Heikenwalder M
    Nature; 2021 Apr; 592(7854):450-456. PubMed ID: 33762733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
    Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K
    Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade.
    Jeon SH; You G; Park J; Chung Y; Park K; Kim H; Jeon J; Kim Y; Son WC; Jeong DS; Shin EC; Lee JY; Han DH; Jung J; Park SH
    Clin Cancer Res; 2024 Sep; 30(18):4155-4166. PubMed ID: 38743752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
    Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
    Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.
    Rimassa L; Abbadessa G; Personeni N; Porta C; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; De Toni EN; Weiss A; Miles S; Gasbarrini A; Lencioni M; Lamar ME; Wang Y; Shuster D; Schwartz BE; Santoro A
    Oncotarget; 2016 Nov; 7(45):72622-72633. PubMed ID: 27579536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tivantinib (ARQ197) in hepatocellular carcinoma.
    Porta C; Giglione P; Ferrari A; Reversi F; Liguigli W; Imarisio I; Ganini C
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):615-22. PubMed ID: 26035719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upregulation of PD‑L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300‑mediated NF‑κB signaling.
    Lucas J; Hsieh TC; Halicka HD; Darzynkiewicz Z; Wu JM
    Int J Oncol; 2018 Oct; 53(4):1469-1480. PubMed ID: 30066852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanobody against PDL1.
    Li S; Jiang K; Wang T; Zhang W; Shi M; Chen B; Hua Z
    Biotechnol Lett; 2020 May; 42(5):727-736. PubMed ID: 32006351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity
    Rebouissou S; La Bella T; Rekik S; Imbeaud S; Calatayud AL; Rohr-Udilova N; Martin Y; Couchy G; Bioulac-Sage P; Grasl-Kraupp B; de Koning L; Ganne-Carrié N; Nault JC; Ziol M; Zucman-Rossi J
    Clin Cancer Res; 2017 Aug; 23(15):4364-4375. PubMed ID: 28246274
    [No Abstract]   [Full Text] [Related]  

  • 35. Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.
    Lu S; Török HP; Gallmeier E; Kolligs FT; Rizzani A; Arena S; Göke B; Gerbes AL; De Toni EN
    Oncotarget; 2015 Sep; 6(26):22167-78. PubMed ID: 26259250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
    Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
    Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
    Moon EK; Langer CJ; Albelda SM
    Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers.
    Rimassa L; Santoro A; Daniele B; Germano D; Gasbarrini A; Salvagni S; Masi G; Abbadessa G; Lamar M; Goldberg T; Porta C
    Tumori; 2015; 101(2):139-43. PubMed ID: 25838254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice.
    Sasaki K; Nishina S; Yamauchi A; Fukuda K; Hara Y; Yamamura M; Egashira K; Hino K
    Cell Mol Gastroenterol Hepatol; 2021; 11(3):739-762. PubMed ID: 33191170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.